Pharmaceutical Roundup: Abortion Pill Access Battle, UCB Acquires Candid Therapeutics, and More
The U.S. Supreme Court faces a request to restore mail-order access to mifepristone amid legal challenges. UCB acquires Candid Therapeutics for $2.2 b...
The U.S. Supreme Court faces a request to restore mail-order access to mifepristone amid legal challenges. UCB acquires Candid Therapeutics for $2.2 b...
Astellas is reentering clinical trials for its next-generation XLMTM gene therapy following patient deaths. Eli Lilly acquires Ajax Therapeutics for u...